Tysabri and PML: Key Questions for Your Care Team

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Understanding the Legacy of Health Information and Tysabri Risk

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection has been recognized for decades in the context of immunosuppression, and its association with certain biologic therapies is well-documented in medical literature. This page outlines what PML is, its symptoms, and how it relates to Tysabri treatment, so you can have informed conversations with your healthcare team.

Medical Evidence: Tysabri and Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus. The following narrative integrates clinical, pharmacological, and risk-related evidence to inform patients and their legal representatives. Progressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system that typically occurs in immunocompromised individuals. Clinical presentation often includes progressive neurological deficits such as weakness, gait disturbance, cognitive decline, visual loss, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri is a monoclonal antibody that binds to alpha-4 integrin, inhibiting lymphocyte migration into the brain. This mechanism reduces inflammation in multiple sclerosis but also impairs immune surveillance against JC virus. The FDA-approved labeling includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.

Mechanistic Pathway and Risk Factors for PML

The mechanistic pathway linking Tysabri to PML involves reduced immune surveillance in the central nervous system. By blocking lymphocyte trafficking, Tysabri limits the ability of the immune system to control JC virus reactivation. This allows the virus to infect oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients who are seropositive for anti-JCV antibodies, indicating prior exposure to the virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Adverse event reports from the FDA Adverse Event Reporting System (FAERS) list fatigue, multiple sclerosis relapse, headache, gait disturbance, and fall as the most frequently reported events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these are not specific to PML, they underscore the range of neurological symptoms that may be reported by patients. PML itself occurred in three patients during clinical trials: two in multiple sclerosis patients treated for a median of 120 weeks (who also received interferon beta-1a) and one in a Crohn's disease patient after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Legal Considerations

The adequacy of warnings regarding Tysabri and PML is a critical risk consideration. The boxed warning explicitly states that Tysabri increases the risk of PML and that it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The labeling also instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether patients were adequately informed of the risk, particularly in the context of long-term therapy or prior immunosuppressant use. For patients who develop PML after Tysabri treatment, attorney-related considerations include the timeline between exposure and documented harm. PML can occur after varying durations of therapy, with risk increasing beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical trials reported cases at 120 weeks and after eight doses, indicating that PML can occur both early and late in treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Legal evaluation may focus on whether the prescribing physician followed monitoring guidelines and whether the patient was informed of the risk factors.

Summary of Evidence and Legal Context

In summary, Tysabri is associated with a known risk of PML, a severe brain infection. The FDA labeling provides clear warnings and risk factors, but patients who develop PML may need to explore legal options regarding informed consent and medical management. Evidence from clinical trials and adverse event reports supports the link between Tysabri and PML, with a timeline that can extend from months to years after treatment initiation. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962 https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA labeling includes a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options are available for patients who developed PML after Tysabri?

Patients may seek legal advice regarding informed consent and medical management. An attorney can evaluate whether the prescribing physician followed monitoring guidelines and whether the patient was adequately informed of the risks. This is particularly relevant in North Carolina.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.